Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Abstract Background Radium-223, a targeted alpha therapy, is used to treat symptomatic patients with castration-resistant prostate cancer (CRPC) and bone metastases. Data for radium-223 in asymptomatic CRPC patients with bone metastases are lacking. Methods This was a prospective, single-arm phase 3...

Full description

Bibliographic Details
Main Authors: Axel Heidenreich, Silke Gillessen, Daniel Heinrich, Daniel Keizman, Joe M. O’Sullivan, Joan Carles, Manfred Wirth, Kurt Miller, John Reeves, Monica Seger, Sten Nilsson, Fred Saad
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Cancer
Subjects:
Radium-223
mCRPC, asymptomatic
Symptomatic
Bone metastases
Online Access:http://link.springer.com/article/10.1186/s12885-018-5203-y

Internet

http://link.springer.com/article/10.1186/s12885-018-5203-y

Similar Items